Heraeus expands its platinum-based HPAPI capacity

Company's multimillion euro investment will enable it to meet growing market demands from clients providing cancer treatments.

Heraeus is the leading market supplier for Platinum-based HPAPIs, which are a key component used in cancer chemotherapy. As cancer cases rise across the globe, Heraeus has increased its production capabilities to ensure it leads the drive for much-needed capacity to meet the long-term global market demand.

The technical set-up of the new production line is now complete and commercial production is scheduled to begin in 2020 upon completion of the validation process.

Dr Marcus Hannakam, Head of Heraeus’ Pharmaceutical Ingredients Business Line said: “This multimillion euro investment in additional capacity underlines our commitment to lead in this field and help our customers in the vital job of providing the drugs to treat cancer patients across the globe.

“We have a proud tradition in high-quality precious metal technologies and a continued focus on fostering long-term partnerships with our customers who work on therapies to fight cancer.

“With the technical set-up of our new production line now complete, we are primed and ready to meet the growing market demands from our clients for platinum-based HPAPIs and lifesaving treatments for cancer patients.”

Platinum-based HPAPIs are used in chemotherapy treatments to combat a range of cancers, including lung, colorectal, ovarian and testicular cancer. The need for these particular HPAPIs in cancer treatment has been rocketing due to demographic changes leading to more cancer cases, emerging countries gaining access to chemotherapy and usage of platinum-based HPAPIs in combination therapy.